CareDx appoints Dr. Hannah Valantine to board; co-inventor of AlloSure technology

CareDx, Inc.

Dr. Hannah Valantine appointed as Class I director effective July 1, 2021.
She is Professor of Medicine at Stanford and former NIH Chief Scientific Officer for Workforce Diversity.
She co-invented the donor-derived cell-free DNA technology (AlloSure) for transplant rejection monitoring.
Initial equity grants: option and RSU each with $150,000 grant-date fair value; annual cash retainer $40,000.
She also serves on board of Pacific Biosciences of California (Nasdaq: PACB) since June 2021.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Hannah A. Valantine

Class I Director

CDNA · CareDx, Inc.

Effective: 2021-07-01
Filed: July 1, 2021, 7:59 PM ET

On June 30, 2021, the board of directors (the “Board”) of CareDx, Inc. (the “Company”) appointed Hannah A. Valantine, M.D. as a Class I director of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Hannah A. Valantine was appointed as Class I Director at CareDx, Inc..

Action: appointed
Role: Class I Director

Exact text from the filing

On June 30, 2021, the board of directors (the “Board”) of CareDx, Inc. (the “Company”) appointed Hannah A. Valantine, M.D. as a Class I director of the Company.

View on SEC.gov

CareDx, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-21-206325

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.